Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + onartuzumab
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Erlotinib + onartuzumab is a combination therapy consisting of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and onartuzumab, a monoclonal antibody targeting the hepatocyte growth factor receptor (MET). This combination was investigated primarily for the treatment of non-small-cell lung cancer (NSCLC), particularly in patients with MET-positive tumors. Erlotinib inhibits EGFR signaling to block tumor cell proliferation and survival, while onartuzumab blocks MET signaling implicated in resistance to EGFR inhibitors and poor prognosis. The rationale for combining these agents was to overcome resistance mechanisms mediated by MET activation. Clinical trials showed mixed results; phase II data suggested benefit in MET-positive NSCLC patients, but subsequent phase III studies failed to demonstrate improved outcomes compared to erlotinib alone[1][2][5][6].
- Brand names
- onartuzumaberlotinib
- Other names
- onartuzumab + erlotinib
02
Targets
EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on erlotinib + onartuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + onartuzumab.